TY  - JOUR
A1  - Chen, Xinyu
A1  - Werner, Rudolf A.
A1  - Javadi, Mehrbod S.
A1  - Maya, Yoshifumi
A1  - Decker, Michael
A1  - Lapa, Constantin
A1  - Herrmann, Ken
A1  - Higuchi, Takahiro
T1  - Radionuclide imaging of neurohormonal system of the heart
JF  - Theranostics
N2  - Heart failure is one of the growing causes of death especially in developed countries due to longer life expectancy. Although many pharmacological and instrumental therapeutic approaches have been introduced for prevention and treatment of heart failure, there are still limitations and challenges. Nuclear cardiology has experienced rapid growth in the last few decades, in particular the application of single photon emission computed tomography (SPECT) and positron emission tomography (PET), which allow non-invasive functional assessment of cardiac condition including neurohormonal systems involved in heart failure; its application has dramatically improved the capacity for fundamental research and clinical diagnosis. In this article, we review the current status of applying radionuclide technology in non-invasive imaging of neurohormonal system in the heart, especially focusing on the tracers that are currently available. A short discussion about disadvantages and perspectives is also included.
KW  - SPECT
KW  - radiotracer
KW  - heart failure
KW  - cardiac neurohormonal system
KW  - nuclear cardiology
KW  - PET
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-149205
VL  - 5
IS  - 6
ER  - 
TY  - JOUR
A1  - Werner, Rudolf A.
A1  - Chen, Xinyu
A1  - Rowe, Steven P.
A1  - Lapa, Constantin
A1  - Javadi, Mehrbod S.
A1  - Higuchi, Takahiro
T1  - Moving into the Next Era of PET Myocardial Perfusion Imaging - Introduction of Novel \(^{18}\)F-labeled Tracers
JF  - The International Journal of Cardiovascular Imaging
N2  - The heart failure (HF) epidemic continues to rise with coronary artery disease (CAD) as one of its main causes. Novel concepts for risk stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial perfusion imaging (MPI) using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolution and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 sec), oxygen-15 water (2 min) or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel 18F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise testing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel 18F-labeled perfusion radiotracers will be discussed.
KW  - heart failure with mid-range ejection fraction
KW  - Positronenemissionstomografie
KW  - coronary artery disease
KW  - precision medicine
KW  - positron emission tomography
KW  - PET
KW  - SPECT
KW  - myocardial perfusion imaging
KW  - MPI
KW  - 18F-flurpiridaz
KW  - 18FFBnTP
KW  - HFmrEF
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-169134
SN  - 1569-5794
ER  -